Dual therapy with anti‐CGRP monoclonal antibodies and botulinum toxin for migraine prevention: is there a rationale?

L Pellesi, TP Do, H Ashina, M Ashina… - … : The Journal of Head …, 2020 - Wiley Online Library
Objective To narratively review the pathophysiological rationale of dual therapy with anti‐
calcitonin gene‐related peptide monoclonal antibodies and botulinum toxin type A in …
被引用次数：81 相关文章

Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

L Pellesi, TP Do, H Ashina, M Ashina, R Burstein - Headache, 2020 - research.regionh.dk
OBJECTIVE: To narratively review the pathophysiological rationale of dual therapy with anti-
calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A in …

Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

L Pellesi, TP Do, H Ashina, M Ashina… - Headache: The Journal …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective</jats: title>< jats: p> To narratively review the
pathophysiological rationale of dual therapy with anti‐calcitonin gene‐related peptide …
[PDF] researchgate.net

[PDF][PDF] Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

L Pellesi, TP Do, H Ashina, M Ashina, R Burstein - 2020 - researchgate.net
Objective.—To narratively review the pathophysiological rationale of dual therapy with anti-
calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A in …

Dual Therapy With Anti‐CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

L Pellesi, TP Do, H Ashina, M Ashina… - … : The Journal of Head …, 2020 - search.ebscohost.com
Objective: To narratively review the pathophysiological rationale of dual therapy with anti‐
calcitonin gene‐related peptide monoclonal antibodies and botulinum toxin type A in …

Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

L Pellesi, TP Do, H Ashina, M Ashina, R Burstein - Headache, 2020 - europepmc.org
Objective To narratively review the pathophysiological rationale of dual therapy with anti-
calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A in …

Dual Therapy With Anti-CGRP Monoclonal Antibodies and Botulinum Toxin for Migraine Prevention: Is There a Rationale?

L Pellesi, TP Do, H Ashina, M Ashina… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Objective To narratively review the pathophysiological rationale of dual therapy with anti-
calcitonin gene-related peptide monoclonal antibodies and botulinum toxin type A in …